Selective liver X receptor modulators (SLiMs): What use in human health?

Molecular and Cellular Endocrinology

Volumn 351, Issue 2, 2012, Pages 129-141

  Viennois, Emilie ^a,b,c   Mouzat, Kevin ^d   Dufour, Julie ^a,b,c   Morel, Laurent ^a,b,c   Lobaccaro, Jean Marc ^a,b,c   Baron, Silvère ^a,b,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b CNRS   (France)

^c CRNH AUVERGNE   (France)

^d DEPARTMENT OF NEUROLOGY   (France)

Author keywords

Cholesterol; Human pathologies; Liver X receptors; Nuclear receptors; Pharmacology; SLiMs

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; ACANTHOIC ACID; ERGOST 22 ENE 1ALPHA,2BETA DIOL; ERGOSTAN 4,6,8,22 TETRAEN 3 ONE; GW 6340; GYNOSAPONIN TR1; HONOKIOL; HORMONE RECEPTOR STIMULATING AGENT; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LXR 623; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; N,N DIMETHYL 3BETA HYDROXYCHOLENAMIDE; OXYSTEROL; PAXILLIN; PODOCARPIC ACID DERIVATIVE; SITOSTANOL; SITOSTEROL; UNCLASSIFIED DRUG; WYE 672; YT 32;

ALZHEIMER DISEASE; ANDROGEN DEPRIVATION THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; BINDING AFFINITY; BREAST CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; COLON CANCER; DERMATITIS; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FATTY ACID SYNTHESIS; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOMODULATION; INFLAMMATION; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHOTOAGING; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE; STEROIDOGENESIS;

ALZHEIMER DISEASE; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; DIABETES MELLITUS; FATTY ACIDS; GLUCOSE; HUMANS; INFLAMMATION; LIGANDS; LIPID METABOLISM; MICE; NEOPLASMS; ORPHAN NUCLEAR RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SKIN DISEASES; STEROIDS;

EID: 84857139806     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.08.036     Document Type: Review

References (127)

1. Adighibe O., Arepalli S., Duckworth J., Hardy J., Wavrant-De Vrieze F. Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease. Neurobiol. Aging 2006, 27:1431-1434.
2. Barbier O., Trottier J., Kaeding J., Caron P., Verreault M. Lipid-activated transcription factors control bile acid glucuronidation. Mol. Cell. Biochem. 2009, 326:3-8.
3. Berrodin T.J., Shen Q., Quinet E.M., Yudt M.R., Freedman L.P., Nagpal S. Identification of 5alpha, 6alpha-epoxycholesterol as a novel modulator of liver X receptor activity. Mol. Pharmacol. 2010, 78:1046-1058.
4. Birrell M.A., Catley M.C., Hardaker E., Wong S., Willson T.M., McCluskie K., Leonard T., Farrow S.N., Collins J.L., Haj-Yahia S., Belvisi M.G. Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J. Biol. Chem. 2007, 282:31882-31890.
5. Bramlett K.S., Houck K.A., Borchert K.M., Dowless M.S., Kulanthaivel P., Zhang Y., Beyer T.P., Schmidt R., Thomas J.S., Michael L.F., Barr R., Montrose C., Eacho P.I., Cao G., Burris T.P. A natural product ligand of the oxysterol receptor, liver X receptor. J. Pharmacol. Exp. Ther. 2003, 307:291-296.
6. Bravi F., Scotti L., Bosetti C., Talamini R., Negri E., Montella M., Franceschi S., La Vecchia C. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann. Oncol. 2006, 17:1014-1017.
7. Cao G., Liang Y., Broderick C.L., Oldham B.A., Beyer T.P., Schmidt R.J., Zhang Y., Stayrook K.R., Suen C., Otto K.A., Miller A.R., Dai J., Foxworthy P., Gao H., Ryan T.P., Jiang X.C., Burris T.P., Eacho P.I., Etgen G.J. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 2003, 278:1131-1136.
8. Cha J.Y., Repa J.J. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 2007, 282:743-751.
9. Chang K.C., Shen Q., Oh I.G., Jelinsky S.A., Jenkins S.F., Wang W., Wang Y., LaCava M., Yudt M.R., Thompson C.C., Freedman L.P., Chung J.H., Nagpal S. Liver X receptor is a therapeutic target for photoaging and chronological skin aging. Mol. Endocrinol. 2008, 22:2407-2419.
10. Chen W., Chen G., Head D.L., Mangelsdorf D.J., Russell D.W. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 2007, 5:73-79.
11. Chuu C.P. Modulation of liver X receptor signaling as a prevention and therapy for colon cancer. Med. Hypotheses 2011, 76:697-699.
12. Coffey D.S. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology 2001, 57:31-38.
13. Crisafulli C., Mazzon E., Paterniti I., Galuppo M., Bramanti P., Cuzzocrea S. Effects of liver X receptor agonist treatment on signal transduction pathways in acute lung inflammation. Respir. Res. 2010, 11:19.
14. Cummins C.L., Volle D.H., Zhang Y., McDonald J.G., Sion B., Lefrancois-Martinez A.M., Caira F., Veyssiere G., Mangelsdorf D.J., Lobaccaro J.M. Liver X receptors regulate adrenal cholesterol balance. J. Clin. Invest. 2006, 116:1902-1912.
15. Dahlman I., Nilsson M., Jiao H., Hoffstedt J., Lindgren C.M., Humphreys K., Kere J., Gustafsson J.A., Arner P., Dahlman-Wright K. Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity. Pharmacogenet. Genomics 2006, 16:881-889.
16. Dave V.P., Kaul D., Sharma Y., Bhattacharya R. Functional genomics of blood cellular LXR-alpha gene in human coronary heart disease. J. Mol. Cell. Cardiol. 2009, 46:536-544.
17. Demerjian M., Choi E.H., Man M.Q., Chang S., Elias P.M., Feingold K.R. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp. Dermatol. 2009, 18:643-649.
18. DiBlasio-Smith E.A., Arai M., Quinet E.M., Evans M.J., Kornaga T., Basso M.D., Chen L., Feingold I., Halpern A.R., Liu Q.Y., Nambi P., Savio D., Wang S., Mounts W.M., Isler J.A., Slager A.M., Burczynski M.E., Dorner A.J., LaVallie E.R. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J. Transl. Med. 2008, 6:59.
19. Donkin J.J., Stukas S., Hirsch-Reinshagen V., Namjoshi D., Wilkinson A., May S., Chan J., Fan J., Collins J., Wellington C.L. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J. Biol. Chem. 2010, 285:34144-34154.
20. El-Hajjaji F.Z., Oumeddour A., Pommier A.J., Ouvrier A., Viennois E., Dufour J., Caira F., Drevet J.R., Volle D.H., Baron S., Saez F., Lobaccaro J.M. Liver X receptors, lipids and their reproductive secrets in the male. Biochim. Biophys. Acta 2011, 1812:974-981.
21. Fitz N.F., Cronican A., Pham T., Fogg A., Fauq A.H., Chapman R., Lefterov I., Koldamova R. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J. Neurosci. 2010, 30:6862-6872.
22. Fukuchi J., Hiipakka R.A., Kokontis J.M., Hsu S., Ko A.L., Fitzgerald M.L., Liao S. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res. 2004, 64:7682-7685.
23. Fukuchi J., Kokontis J.M., Hiipakka R.A., Chuu C.P., Liao S. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 2004, 64:7686-7689.
24. Giannarelli, C., Cimmino, G., Connolly, T.M., Ibanez, B., Garcia Ruiz, J.M., Alique, M., Zafar, M.U., Fuster, V., Feuerstein, G. Badimon, J.J., 2011. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J. [Epub ahead of print].
25. Goldwasser J., Cohen P.Y., Yang E., Balaguer P., Yarmush M.L., Nahmias Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha. PLoS One 2010, 5:e12399.
26. Gong H., Guo P., Zhai Y., Zhou J., Uppal H., Jarzynka M.J., Song W.C., Cheng S.Y., Xie W. Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor. Mol. Endocrinol. 2007, 21:1781-1790.
27. Gronberg H. Prostate cancer epidemiology. Lancet 2003, 361:859-864.
28. Hanley K., Ng D.C., He S.S., Lau P., Min K., Elias P.M., Bikle D.D., Mangelsdorf D.J., Williams M.L., Feingold K.R. Oxysterols induce differentiation in human keratinocytes and increase Ap-1-dependent involucrin transcription. J. Invest. Dermatol. 2000, 114:545-553.
29. Hannedouche S., Zhang J., Yi T., Shen W., Nguyen D., Pereira J.P., Guerini D., Baumgarten B.U., Roggo S., Wen B., Knochenmuss R., Noel S., Gessier F., Kelly L.M., Vanek M., Laurent S., Preuss I., Miault C., Christen I., Karuna R., Li W., Koo D.I., Suply T., Schmedt C., Peters E.C., Falchetto R., Katopodis A., Spanka C., Roy M.O., Detheux M., Chen Y.A., Schultz P.G., Cho C.Y., Seuwen K., Cyster J.G., Sailer A.W. Oxysterols direct immune cell migration via EBI2. Nature 2011, 475:524-527.
30. Hatano, Y., Man, M.Q., Uchida, Y., Crumrine, D., Mauro, T.M., Feingold, K.R., Elias, P.M. Holleran, W.M., 2010. Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J. Allergy Clin. Immunol. 125, 160 e-1-169 e-5.
31. Herath K., Jayasuriya H., Ondeyka J.G., Guan Z., Borris R.P., Stijfhoorn E., Stevenson D., Wang J., Sharma N., Macnaul K., Menke J.G., Ali A., Schulman M.J., Singh S.B. Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand. J. Nat. Prod. 2005, 68:617-619.
32. Houck K.A., Borchert K.M., Hepler C.D., Thomas J.S., Bramlett K.S., Michael L.F., Burris T.P. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab. 2004, 83:184-187.
33. Hu B., Unwalla R.J., Goljer I., Jetter J.W., Quinet E.M., Berrodin T.J., Basso M.D., Feingold I.B., Nilsson A.G., Wilhelmsson A., Evans M.J., Wrobel J.E. Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist. J. Med. Chem. 2010, 53:3296-3304.
34. Hu X., Li S., Wu J., Xia C., Lala D.S. Liver X receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 2003, 17:1019-1026.
35. Huang T.H., Razmovski-Naumovski V., Salam N.K., Duke R.K., Tran V.H., Duke C.C., Roufogalis B.D. A novel LXR-alpha activator identified from the natural product Gynostemma pentaphyllum. Biochem. Pharmacol. 2005, 70:1298-1308.
36. Infante J., Rodriguez-Rodriguez E., Mateo I., Llorca J., Vazquez-Higuera J.L., Berciano J., Combarros O. Gene-gene interaction between heme oxygenase-1 and liver X receptor-beta and Alzheimer's disease risk. Neurobiol. Aging 2010, 31:710-714.
37. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
38. Janowski B.A., Grogan M.J., Jones S.A., Wisely G.B., Kliewer S.A., Corey E.J., Mangelsdorf D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. USA 1999, 96:266-271.
39. Jayasuriya H., Herath K.B., Ondeyka J.G., Guan Z., Borris R.P., Tiwari S., de Jong W., Chavez F., Moss J., Stevenson D.W., Beck H.T., Slattery M., Zamora N., Schulman M., Ali A., Sharma N., MacNaul K., Hayes N., Menke J.G., Singh S.B. Diterpenoid, steroid, and triterpenoid agonists of liver X receptors from diversified terrestrial plants and marine sources. J. Nat. Prod. 2005, 68:1247-1252.
40. Jiang Y.J., Lu B., Kim P., Elias P.M., Feingold K.R. Regulation of ABCA1 expression in human keratinocytes and murine epidermis. J. Lipid Res. 2006, 47:2248-2258.
41. Jiang Y.J., Lu B., Tarling E.J., Kim P., Man M.Q., Crumrine D., Edwards P.A., Elias P.M., Feingold K.R. Regulation of ABCG1 expression in human keratinocytes and murine epidermis. J. Lipid Res. 2010, 51:3185-3195.
42. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
43. Joseph S.B., Laffitte B.A., Patel P.H., Watson M.A., Matsukuma K.E., Walczak R., Collins J.L., Osborne T.F., Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 2002, 277:11019-11025.
44. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., Law R.E., Collins J.L., Willson T.M., Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 2002, 99:7604-7609.
45. Joseph S.B., Bradley M.N., Castrillo A., Bruhn K.W., Mak P.A., Pei L., Hogenesch J., O'Connell R M., Cheng G., Saez E., Miller J.F., Tontonoz P. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004, 119:299-309.
46. Kaneko E., Matsuda M., Yamada Y., Tachibana Y., Shimomura I., Makishima M. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J. Biol. Chem. 2003, 278:36091-36098.
47. Kase E.T., Wensaas A.J., Aas V., Hojlund K., Levin K., Thoresen G.H., Beck-Nielsen H., Rustan A.C., Gaster M. Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway. Diabetes 2005, 54:1108-1115.
48. Katz A., Udata C., Ott E., Hickey L., Burczynski M.E., Burghart P., Vesterqvist O., Meng X. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J. Clin. Pharmacol. 2009, 49:643-649.
49. Ketterer C., Mussig K., Machicao F., Stefan N., Fritsche A., Haring H.U., Staiger H. Genetic variation within the NR1H2 gene encoding liver X receptor beta associates with insulin secretion in subjects at increased risk for type 2 diabetes. J. Mol. Med. 2011, 89:75-81.
50. Kim K.H., Choi S.H., Lee T.S., Oh W.K., Kim D.S., Kim J.B. Selective LXRalpha inhibitory effects observed in plant extracts of MEH184 (Parthenocissua tricuspidata) and MEH185 (Euscaphis japonica). Biochem. Biophys. Res. Commun. 2006, 349:513-518.
51. Koldamova R., Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach. Curr. Alzheimer Res. 2007, 4:171-178.
52. Koldamova R.P., Lefterov I.M., Staufenbiel M., Wolfe D., Huang S., Glorioso J.C., Walter M., Roth M.G., Lazo J.S. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 2005, 280:4079-4088.
53. Komuves L.G., Schmuth M., Fowler A.J., Elias P.M., Hanley K., Man M.Q., Moser A.H., Lobaccaro J.M., Williams M.L., Mangelsdorf D.J., Feingold K.R. Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J. Invest. Dermatol. 2002, 118:25-34.
54. Kotani H., Tanabe H., Mizukami H., Makishima M., Inoue M. Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. J. Nat. Prod. 2010, 73:1332-1336.
55. Krycer J.R., Brown A.J. Crosstalk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasis. J. Biol. Chem. 2011, 286:20637-20647.
56. Kumar N., Solt L.A., Conkright J.J., Wang Y., Istrate M.A., Busby S.A., Garcia-Ordonez R.D., Burris T.P., Griffin P.R. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol. Pharmacol. 2010, 77:228-236.
57. Laffitte B.A., Chao L.C., Li J., Walczak R., Hummasti S., Joseph S.B., Castrillo A., Wilpitz D.C., Mangelsdorf D.J., Collins J.L., Saez E., Tontonoz P. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA 2003, 100:5419-5424.
58. Lazar M.A. Nuclear receptor corepressors. Nucl. Recept. Signal 2003, 1:e001.
59. Lee S., Lee J., Lee S.K., Lee J.W. Activating signal cointegrator-2 is an essential adaptor to recruit histone H3 lysine 4 methyltransferases MLL3 and MLL4 to the liver X receptors. Mol. Endocrinol. 2008, 22:1312-1319.
60. Lee J.H., Park S.M., Kim O.S., Lee C.S., Woo J.H., Park S.J., Joe E.H., Jou I. Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol. Cell. 2009, 35. 806-17.
61. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272:3137-3140.
62. Leoni V., Caccia C. Oxysterols as biomarkers in neurodegenerative diseases. Chem. Phys. Lipids. 2011, 164:515-524.
63. Li X., Zhang S., Blander G., Tse J.G., Krieger M., Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 2007, 28:91-106.
64. Li X., Yeh V., Molteni V. Liver X receptor modulators: a review of recently patented compounds (2007-2009). Expert Opin. Ther. Pat. 2010, 20:535-562.
65. Liu C., Yang X.V., Wu J., Kuei C., Mani N.S., Zhang L., Yu J., Sutton S.W., Qin N., Banie H., Karlsson L., Sun S., Lovenberg T.W. Oxysterols direct B-cell migration through EBI2. Nature 2011, 475:519-523.
66. Lo Sasso G., Murzilli S., Salvatore L., D'Errico I., Petruzzelli M., Conca P., Jiang Z.Y., Calabresi L., Parini P., Moschetta A. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010, 12:187-193.
67. Magura L., Blanchard R., Hope B., Beal J.R., Schwartz G.G., Sahmoun A.E. Hypercholesterolemia and prostate cancer: a hospital-based case-control study. Cancer Causes Control 2008, 19:1259-1266.
68. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
69. Misra A., Khurana L. Obesity and the metabolic syndrome in developing countries. J. Clin. Endocrinol. Metab. 2008, 93:S9-30.
70. Mitro N., Vargas L., Romeo R., Koder A., Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 2007, 581:1721-1726.
71. Morales J.R., Ballesteros I., Deniz J.M., Hurtado O., Vivancos J., Nombela F., Lizasoain I., Castrillo A., Moro M.A. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 2008, 118:1450-1459.
72. Morello F., de Boer R.A., Steffensen K.R., Gnecchi M., Chisholm J.W., Boomsma F., Anderson L.M., Lawn R.M., Gustafsson J.A., Lopez-Ilasaca M., Pratt R.E., Dzau V.J. Liver X receptors alpha and beta regulate renin expression in vivo. J. Clin. Invest. 2005, 115:1913-1922.
73. Motoshima K., Noguchi-Yachide T., Sugita K., Hashimoto Y., Ishikawa M. Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists. Bioorg. Med. Chem. 2009, 17:5001-5014.
74. Noguchi-Yachide T., Aoyama A., Makishima M., Miyachi H., Hashimoto Y. Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:3957-3961.
75. Ondeyka J.G., Jayasuriya H., Herath K.B., Guan Z., Schulman M., Collado J., Dombrowski A.W., Kwon S.S., McCallum C., Sharma N., MacNaul K., Hayes N., Menke J.G., Singh S.B. Steroidal and triterpenoidal fungal metabolites as ligands of liver X receptors. J. Antibiot. (Tokyo) 2005, 58:559-565.
76. Ou J., Tu H., Shan B., Luk A., DeBose-Boyd R.A., Bashmakov Y., Goldstein J.L., Brown M.S. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc. Natl. Acad. Sci. USA 2001, 98:6027-6032.
77. Park M.C., Kwon Y.J., Chung S.J., Park Y.B., Lee S.K. Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. Rheumatology (Oxford) 2010, 49:882-890.
78. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., Mangelsdorf D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
79. Peng D., Hiipakka R.A., Xie J.T., Dai Q., Kokontis J.M., Reardon C.A., Getz G.S., Liao S. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice. Br. J. Pharmacol. 2011, 162:1792-1804.
80. Pfeifer T., Buchebner M., Chandak P.G., Patankar J., Kratzer A., Obrowsky S., Rechberger G.N., Kadam R.S., Kompella U.B., Kostner G.M., Kratky D., Levak-Frank S. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr. Pharm. Biotechnol. 2011, 12:285-292.
81. Plat J., Nichols J.A., Mensink R.P. Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation. J. Lipid Res. 2005, 46:2468-2476.
82. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., Giovannucci E. Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 2006, 98:1819-1825.
83. Pommier A.J., Alves G., Viennois E., Bernard S., Communal Y., Sion B., Marceau G., Damon C., Mouzat K., Caira F., Baron S., Lobaccaro J.M. Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 2010, 29:2712-2723.
84. Qin Y., Dalen K.T., Gustafsson J.A., Nebb H.I. Regulation of hepatic fatty acid elongase 5 by LXRalpha-SREBP-1c. Biochim. Biophys. Acta 2009, 1791:140-147.
85. Quinet E.M., Savio D.A., Halpern A.R., Chen L., Miller C.P., Nambi P. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J. Lipid Res. 2004, 45:1929-1942.
86. Quinet E.M., Basso M.D., Halpern A.R., Yates D.W., Steffan R.J., Clerin V., Resmini C., Keith J.C., Berrodin T.J., Feingold I., Zhong W., Hartman H.B., Evans M.J., Gardell S.J., DiBlasio-Smith E., Mounts W.M., LaVallie E.R., Wrobel J., Nambi P., Vlasuk G.P. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J. Lipid Res. 2009, 50:2358-2370.
87. Rau K.M., Kang H.Y., Cha T.L., Miller S.A., Hung M.C. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr. Relat. Cancer 2005, 12:511-532.
88. Repa J.J., Mangelsdorf D.J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 2000, 16:459-481.
89. Rough J.J., Monroy M.A., Yerrum S., Daly J.M. Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J. Ovarian Res. 2010, 3:13.
90. Ruan B., Wilson W.K., Schroepfer G.J. An alternative synthesis of 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol, an intermediate in sterol biosynthesis and a reported activator of meiosis and of nuclear orphan receptor LXR alpha. Bioorg. Med. Chem. Lett. 1998, 8:233-236.
91. Schroepfer G.J. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 2000, 80:361-554.
92. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14:2831-2838.
93. Shannon J., Tewoderos S., Garzotto M., Beer T.M., Derenick R., Palma A., Farris P.E. Statins and prostate cancer risk: a case-control study. Am. J. Epidemiol. 2005, 162:318-325.
94. Shenoy S.D., Spencer T.A., Mercer-Haines N.A., Alipour M., Gargano M.D., Runge-Morris M., Kocarek T.A. CYP3A induction by liver X receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor. Drug Metab. Dispos. 2004, 32:66-71.
95. Shinar D.M., Endo N., Rutledge S.J., Vogel R., Rodan G.A., Schmidt A. NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene 1994, 147:273-276.
96. Singh S.B., Ondeyka J.G., Liu W., Chen S., Chen T.S., Li X., Bouffard A., Dropinski J., Jones A.B., McCormick S., Hayes N., Wang J., Sharma N., Macnaul K., Hernandez M., Chao Y.S., Baffic J., Lam M.H., Burton C., Sparrow C.P., Menke J.G. Discovery and development of dimeric podocarpic acid leads as potent agonists of liver X receptor with HDL cholesterol raising activity in mice and hamsters. Bioorg. Med. Chem. Lett. 2005, 15:2824-2828.
97. Sironi L., Mitro N., Cimino M., Gelosa P., Guerrini U., Tremoli E., Saez E. Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS Lett. 2008, 582:3396-3400.
98. Song C., Kokontis J.M., Hiipakka R.A., Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 1994, 91:10809-10813.
99. Song C., Hiipakka R.A., Liao S. Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 2000, 65:423-427.
100. Song C., Liao S. Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 2000, 141:4180-4184.
101. Song C., Hiipakka R.A., Liao S. Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids 2001, 66:473-479.
102. Spector D., Anthony M., Alexander D., Arab L. Soy consumption and colorectal cancer. Nutr. Cancer 2003, 47:1-12.
103. Spyridon M., Moraes L.A., Jones C.I., Sage T., Sasikumar P., Bucci G., Gibbins J.M. LXR as a novel antithrombotic target. Blood 2011, 117:5751-5761.
104. Stein S., Matter C.M. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011, 10:640-647.
105. Sticozzi C., Pecorelli A., Belmonte G., Valacchi G. Cigarette smoke affects ABCAl expression via liver X receptor nuclear translocation in human keratinocytes. Int. J. Mol. Sci. 2010, 11:3375-3386.
106. Svensson S., Ostberg T., Jacobsson M., Norstrom C., Stefansson K., Hallen D., Johansson I.C., Zachrisson K., Ogg D., Jendeberg L. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 2003, 22:4625-4633.
107. Tamehiro N., Sato Y., Suzuki T., Hashimoto T., Asakawa Y., Yokoyama S., Kawanishi T., Ohno Y., Inoue K., Nagao T., Nishimaki-Mogami T. Riccardin C: a natural product that functions as a liver X receptor (LXR)alpha agonist and an LXRbeta antagonist. FEBS Lett. 2005, 579:5299-5304.
108. Tamura K., Chen Y.E., Horiuchi M., Chen Q., Daviet L., Yang Z., Lopez-Ilasaca M., Mu H., Pratt R.E., Dzau V.J. LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. Proc. Natl. Acad. Sci. USA 2000, 97:8513-8518.
109. Thomas J., Bramlett K.S., Montrose C., Foxworthy P., Eacho P.I., McCann D., Cao G., Kiefer A., McCowan J., Yu K.L., Grese T., Chin W.W., Burris T.P., Michael L.F. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor. J. Biol. Chem. 2003, 278:2403-2410.
110. Traves P.G., Hortelano S., Zeini M., Chao T.H., Lam T., Neuteboom S.T., Theodorakis E.A., Palladino M.A., Castrillo A., Bosca L. Selective activation of liver X receptors by acanthoic acid-related diterpenes. Mol. Pharmacol. 2007, 71:1545-1553.
111. Uno S., Endo K., Jeong Y., Kawana K., Miyachi H., Hashimoto Y., Makishima M. Suppression of beta-catenin signaling by liver X receptor ligands. Biochem. Pharmacol. 2009, 77:186-195.
112. Vedin L.L., Lewandowski S.A., Parini P., Gustafsson J.A., Steffensen K.R. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 2009, 30:575-579.
113. Viennois E., Pommier A.J., Mouzat K., Oumeddour A., El Hajjaji F.Z., Dufour J., Caira F., Volle D.H., Baron S., Lobaccaro J.M. Targeting liver X receptors in human health: deadlock or promising trail?. Expert. Opin. Ther. Targets 2011, 15:219-232.
114. Volle D.H., Repa J.J., Mazur A., Cummins C.L., Val P., Henry-Berger J., Caira F., Veyssiere G., Mangelsdorf D.J., Lobaccaro J.M. Regulation of the aldo-keto reductase gene akr1b7 by the nuclear oxysterol receptor LXRalpha (liver X receptor-alpha) in the mouse intestine: putative role of LXRs in lipid detoxification processes. Mol. Endocrinol. 2004, 18:888-898.
115. Volle D.H., Lobaccaro J.M. Role of the nuclear receptors for oxysterols LXRs in steroidogenic tissues: beyond the " foie gras" , the steroids and sex?. Mol. Cell. Endocrinol. 2007, 265-266:183-189.
116. Wang Y., Rogers P.M., Stayrook K.R., Su C., Varga G., Shen Q., Nagpal S., Burris T.P. The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene. Mol. Pharmacol. 2008, 74:1716-1721.
117. Wang Y., Rogers P.M., Su C., Varga G., Stayrook K.R., Burris T.P. Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha. J. Biol. Chem. 2008, 283:26332-26339.
118. Watanabe M., Nakayama T., Shiraishi T., Stemmermann G.N., Yatani R. Comparative studies of prostate cancer in Japan versus the United States. A review. Urol. Oncol. 2000, 5:274-283.
119. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995, 9:1033-1045.
120. Willy P.J., Mangelsdorf D.J. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. Genes Dev. 1997, 11:289-298.
121. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57:1439-1443.
122. Yang C., McDonald J.G., Patel A., Zhang Y., Umetani M., Xu F., Westover E.J., Covey D.F., Mangelsdorf D.J., Cohen J.C., Hobbs H.H. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J. Biol. Chem. 2006, 281:27816-27826.
123. Yasuda T., Grillot D., Billheimer J.T., Briand F., Delerive P., Huet S., Rader D.J. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30:781-786.
124. Yoshikawa T., Shimano H., Yahagi N., Ide T., Amemiya-Kudo M., Matsuzaka T., Nakakuki M., Tomita S., Okazaki H., Tamura Y., Iizuka Y., Ohashi K., Takahashi A., Sone H., Osuga Ji J., Gotoda T., Ishibashi S., Yamada N. Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J. Biol. Chem. 2002, 277:1705-1711.
125. Zelcer N., Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 2006, 116:607-614.
126. Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E.G., Landreth G.E., Vinters H.V., Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors. Proc. Natl. Acad. Sci. USA 2007, 104:10601-10606.
127. Zuercher W.J., Buckholz R.G., Campobasso N., Collins J.L., Galardi C.M., Gampe R.T., Hyatt S.M., Merrihew S.L., Moore J.T., Oplinger J.A., Reid P.R., Spearing P.K., Stanley T.B., Stewart E.L., Willson T.M. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J. Med. Chem. 2010, 53:3412-3416.